Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Piotr Ozieranski"'
Autor:
Anju Murayama, Sae Kamamoto, Hiroaki Saito, Erika Yamashita, Yosuke Suzuki, Tetsuya Tanimoto, Piotr Ozieranski, Akihiko Ozaki
Publikováno v:
International Journal of Health Policy and Management, Vol 12, Iss Issue 1, Pp 1-8 (2023)
Background Financial relationships between healthcare institutions and pharmaceutical companies can lead to conflicts of interest (COIs), potentially compromising patients’ care. In Japan, scholarship donations, unique type of payments made to heal
Externí odkaz:
https://doaj.org/article/57e50381adba47d9b19202c8db18e0a3
Publikováno v:
Globalization and Health, Vol 19, Iss 1, Pp 1-42 (2023)
Abstract Background Self-regulation of payment disclosure by pharmaceutical industry trade groups is a major global approach to increasing transparency of financial relationships between drug companies and healthcare professionals and organisations.
Externí odkaz:
https://doaj.org/article/b4de023953e846f09d9881d7fa85f2e6
Publikováno v:
International Journal of Health Policy and Management, Vol 11, Iss 12, Pp 2842-2859 (2022)
Background Creating new therapies often involves drug companies paying healthcare professionals and institutions for research and development (R&D) activities, including clinical trials. However, industry sponsorship can create conflicts of interest
Externí odkaz:
https://doaj.org/article/314f9ed3b52d4c25b21f9408dd6137e4
Publikováno v:
BMJ Open, Vol 13, Iss 10 (2023)
Objectives To explore the views of professional stakeholders on the future of community pharmacy services in England. Specific objectives related to expectations of how community pharmacy services will be provided by 2030 and factors that will influe
Externí odkaz:
https://doaj.org/article/86def441e4af45fcbabeab17c9189238
Publikováno v:
Exploratory Research in Clinical and Social Pharmacy, Vol 11, Iss , Pp 100298- (2023)
Background: An increased role for community pharmacy might bring considerable value to healthcare systems, for example by relieving workload elsewhere in primary care through the provision of medicines-related services. This requires support from app
Externí odkaz:
https://doaj.org/article/2db92b776405423e8678be72a6bf7c27
Publikováno v:
PLoS ONE, Vol 18, Iss 11 (2023)
Externí odkaz:
https://doaj.org/article/922b27536dbf44a9914e60aa42122e8d
Autor:
Akihiko Ozaki, Anju Murayama, Kayo Harada, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto, Piotr Ozieranski
Publikováno v:
Frontiers in Public Health, Vol 9 (2022)
Institutional conflicts of interest (ICOIs) with pharmaceutical companies can bias internal operation of healthcare organizations. Naturally, a scholarship donation—which is a donation scheme unique to Japan, provided to healthcare organizations an
Externí odkaz:
https://doaj.org/article/c237f0bec5f14939a7aae57d02efca33
Autor:
Shai Mulinari, Piotr Ozieranski
Publikováno v:
Big Data & Society, Vol 9 (2022)
How corporations surveil and influence consumers using big data tools is a major area of research and public debate. However, few studies explore it in relation to physicians in the USA, even though they have been surveilled and targeted by the pharm
Externí odkaz:
https://doaj.org/article/8999394111dc43a0857db010c7add127
Publikováno v:
BMJ Open, Vol 11, Iss 12 (2021)
Objectives To examine the accessibility and quality of drug company payment data in Europe.Design Comparative policy review of payment data in countries with different regulatory approaches to disclosure.Setting 37 European countries.Participants Eur
Externí odkaz:
https://doaj.org/article/fa82e284d151473180758fc8ec3d0e82
Publikováno v:
PLoS ONE, Vol 16, Iss 12 (2021)
Although there has been extensive research on pharmaceutical industry payments to healthcare professionals, healthcare organisations with key roles in health systems have received little attention. We seek to contribute to addressing this gap in rese
Externí odkaz:
https://doaj.org/article/d952d105f07e474ea168fbb60e1bf0b1